BMJ evidence-based medicine · 2018 · 38 citations · 15 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeuropsychiatryPsychopharmacologyAttention-deficit/hyperactivity DisorderMedication-assisted TreatmentStimulant PharmacotherapyStimulant TherapyAdhd PharmacotherapyAdhd TreatmentGuideline MethodologyMethylphenidate PharmacologyMethylphenidate TherapyPharmacological TherapySelective Reporting BiasSubjective Value
The National Institute for Health and Care Excellence (NICE) recently updated its guideline on pharmacological treatments for attention deficit hyperactivity disorder (ADHD).The guideline builds on evidence reviews with serious methodological limitations concerning multiplicity, imprecision, selective reporting, and short-term data.Strong clinical practice recommendations for methylphenidate and lisdexamfetamine are informed by GRADE-evaluated, low-quality studies and subjective value judgements.This article critically discusses the updated NICE guideline on pharmacological treatments for ADHD and proposes concrete solutions to address the issues at hand.
15
GRADE guidelines 6. Rating the quality of evidence—imprecision
Gordon Guyatt, Andrew D Oxman, Regina Kunz et al. · Journal of Clinical Epidemiology · 2011 · 2.7K citations
Going from evidence to recommendations
Gordon Guyatt, Andrew D Oxman, Regina Kunz et al. · BMJ · 2008 · 1.8K citations · Full text